Short answer
NOVANTA INC (NOVT) filed its Q3 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jul 3, 2026. Quarterly revenue was $266M (up 10.3% year over year) with net income of $13M.
Q3 2026 key financials · XBRL
- Revenue
- $266M
- +10.3% YoY · +3.1% QoQ
- Net income
- $13M
- +178.9% YoY · −40.6% QoQ
- Operating margin
- 6.8%
- Gross margin
- 45.5%
- EPS (diluted)
- $0.31
- +158.3% YoY · −39.2% QoQ
Source: XBRL data from the NOVANTA INC (NOVT) Q3 2026 10-Q on SEC EDGAR. USD.
NOVANTA INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added geopolitical risk triggered by February 2026 U.S.-Israel-Iran conflict, threatening energy prices, supply chains, cyberattacks, and demand
- Riverpoint Medical integration risk heightened by $1.2 billion upfront consideration and $250 million milestone payment due January 8, 2027
- Rare-earth supply disruption from China export-license delays, causing customer-order delays and higher manufacturing costs
- Acquisition-driven leverage risk, with gross debt rising from $238.8 million to $854.8 million after Riverpoint Medical
- End-market cyclicality risk, with microelectronics and industrial capital equipment downturns potentially reducing customer capital expenditures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NOVANTA INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.